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The study was a retrospective single center study conducted at RK Khan hospital in 
Durban. The primary aim was to look at the incidence of acute myocardial infarction 
(AMI) in the female population in our setting with particular interest in the 
cardiovascular risk profile of female patients presenting with AMI. Data was 
extracted from a computerized database for the duration of the study period, which 
was from 2003 to 2016. Patient anonymity was maintained.  
All adult female patients that presented to the study center during the study period, 
with a diagnosis of AMI, based on the European and American Society of Cardiology 
guidelines, were included in the study. Females with unstable angina were excluded. 
The cardiovascular disease (CVD) risk factor profile was based on the Framingham 
risk profile for CVD and included the following: diabetes mellitus (DM), 
hypertension (HPT), cigarette smoking, dyslipidemia, obesity, a previous history of 
coronary artery disease and positive family histories of DM, HPT and coronary artery 
disease. The study population was broadly categorized into 2 age groups, namely <65 
years of age and >65 years. Both groups were analyzed identically in terms of their 
age, clinical presentation, CVD risk factors, initial electrocardiogram, medical 
therapies and whether or not they were referred for angiogram and/or coronary artery 
bypass surgery. We also divided the study population into those with ST elevation 
myocardial infarction (STEMI) versus Non ST elevation myocardial infarction. In the 
STEMI group we assessed the use of thrombolytic therapy or not. Finally we looked 
at the presence of major adverse cardiac events (MACE) in each of the age groups. 
MACE was defined as follows: Arrhythmias, cardiac failure, cardiogenic shock, 
complete heart block, recurrence of angina or myocardial infarction and death.  
	 VI	
In addition to the primary study aim, by categorizing patients into 2 age groups we 
could determine if there was a difference in CVD risk factor profile and the presence 
of MACE between the younger and older age groups. Finally, by comparing the 
outcome of our study to studies done in male counterparts we were able to see if there 
was a difference in CVD risk profile between male and female patients, which in fact 
there was not. So basically in the presence of the traditional risk factors for coronary 
artery disease (CAD), males and females can be considered at equal risk of 
developing acute myocardial infarction and females are not protected by the cardio-
protective effects of oestrogen hormone in the pre-menopausal age group as was 
previously thought. Females are an understudied population when it comes to 
coronary artery disease and very few studies have been conducted on females with 
cardiac disease. We believe that this study offers some very valuable information with 
regards to cardiac disease in females and that treatment strategies should be targeted 
to include optimizing risk factor control in at-risk females, so that the burden of 
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PART 1: THE REVIEW OF THE LITERATURE 
 
 
Coronary artery disease is one of the leading causes of death and disability 
worldwide.1,2,3 Likewise in South Africa it has become a major cause of morbidity 
and mortality across all ethnic groups.12,15 Although coronary artery disease was 
previously thought to be a disease predominantly affecting males, it is now 
understood that females with underlying cardiovascular risk factors are equally at risk 
of developing coronary artery disease and specifically manifesting as acute 
myocardial infarction.2,16 The traditional and well-studied risk factors for coronary 
artery disease in males, namely diabetes mellitus, hypertension, dyslipidemia, obesity, 
cigarette smoking and a family history of coronary artery disease, appear to play the 
same role in female counterparts.17 Due to the cardio-protective effects of oestrogen, 
coronary artery disease in females generally occurs at an older age than when 
compared to males.2,3 Multiple	 studies	 have	 shown	 that	women	 tend	 to	 present	with	 coronary artery disease on average 6-10 years later than their male 
counterparts.2,5 Studies have also found that the average age of presentation in 
females in developing countries tends to be lower than that of westernized 
countries.17,18 However, although the disease was thought to predominantly affect 
post-menopausal females, younger females can also develop coronary artery disease 
in the presence of significant cardiovascular risk factors. In particular diabetes 
mellitus has been found to be an independent predictor of acute coronary syndrome in 
younger women, increasing their risk by 4 to 5 fold.1 Furthermore smoking is an 
independent predictor of acute coronary syndrome in women less than 40 years of 
age.31 Although, even the presence of a single risk factor can predispose females to 
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the development of coronary artery disease, in particular acute myocardial infarction, 
like with males, the presence of multiple cardiovascular risk factors increases that risk 
significantly.2  
Several studies have shown that females tend to have a higher risk of developing 
complications following acute myocardial infarction and have higher mortality rates 
compared to men.3,5,19,21,22,24,25 
Cardiovascular disease in females is understudied and there is limited data on the 
disease in females. According to a 2013 update on coronary artery disease in women,3 
it was stated that coronary artery disease is the leading cause of mortality in females 
and requires further sex-specific research on the disease.  
Whilst some risk factors like age, sex, genetic factors and family history, are non-
modifiable, it is the modifiable risk factors (diabetes mellitus, hypertension, obesity, 
dyslipidemia and cigarette smoking) that will impact on future outcomes in these 
patients.  Risk factor control is imperative and should be the focus of primary health 
































Coronary artery disease [CAD] is a major cause of morbidity and mortality 
worldwide, and although previously reported to be more common in men, is now 
identified as a leading cause of death and disability in women in the United States.1,2,3 
Significant differences occur between men and women with respect to the 
epidemiology, diagnosis, treatment, and prognosis of CAD. This may explain the 
under-representation of women in many studies on CAD in the past, often leading to 
misdiagnosis and inappropriate treatment.1,5 These factors include that women are less 
likely than men to have typical angina, though the similarities in how men and women 
present with acute myocardial infarction [AMI] are greater than their differences, and 
women may not identify their initial symptoms and therefore may not seek prompt 
medical advice. 4,5 In addition, there is an under-evaluation of both typical and 
atypical symptoms of ischemia in women by clinicians because of gender bias.6 
Generally women with myocardial infarction are about 10 years older than men at the 
time of presentation and carry a greater burden of risk factors.1,2,3  In contrast, while 
myocardial infarction is an uncommon entity in young people, the incidence is higher 
in men less than 45 years of age because women of a similar age group are at lower 
risk due to of the protective influence of circulating oestrogens on the vascular 
endothelium.2 These differences should be taken into account in the care of women 
with CAD.  
Despite the growing evidence on CAD in women from developed countries, there is a 
paucity of data on the prevalence and mortality outcome of CAD in women from 
developing countries like South Africa. This study, therefore, was undertaken to 
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determine the incidence of AMI in women in a regional hospital in Durban, South 























This was a single-center retrospective study conducted at the Coronary Care Unit 
(CCU) at RK Khan Hospital (RKKH) in Chatsworth, Durban, over a 13-year period 
(2003-2016).  
Consecutive female patients with a confirmed diagnosis of acute MI were included in 
the study while those with unstable angina were excluded. Acute MI was defined on 
admission based on a characteristic history of chest pain/ discomfort, 
electrocardiograph (ECG) changes consistent with acute ST or Non ST elevation MI 
(NSTEMI) and elevated cardiac biomarkers, specifically Troponin T levels, as 
outlined by the Joint European Society of Cardiology/ American College of 
Cardiology committee.7 
Ethics approval was obtained from the local ethics committee at the University of 
Kwazulu-Natal prior to commencement of the study, and carried out according to the 




Clinical assessment:  
Demographic and clinical data stored in an electronic database were obtained from all 
patients, including the presence of risk factors such as diabetes mellitus (DM), 
hypertension(HPT), dyslipidemia, smoking, previous angina or MI and a family 
history of vascular disease. Premature atherosclerosis was defined by a history of 
myocardial infarction in either parents, or in siblings or first degree relatives at the 
age of 55 years or younger for males and 65 years or younger for females, whilst a 
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family history of diabetes, hypertension, and cerebrovascular disease was defined as 
these conditions occurring at any age.8 
Current smokers were defined as individuals who had smoked any tobacco within the 
past 12 months leading up to their MI, and former smokers as those who had not 
smoked for at least one year prior to their MI.   
Anthropometric measurements including body mass index [BMI] and waist 
circumference were used to define obesity. The BMI was calculated as weight 
[kilograms] divided by height2 [meters] according to World Health Organisation 
(WHO) guidelines.9 A BMI ≥ 30 kg/m2 was used as a cut-off to indicate obesity. 
Waist circumference was measured midway between the lowest rib and the iliac crest 
on standing subjects, using a soft tape, and the central obesity threshold limits 
proposed by the International Diabetes Federation [IDF] [females ≥ 80 cm] were used 
to define visceral obesity.10 
 
 
Patients with ST elevation MI (STEMI) who were eligible for thrombolysis received 
Metalyse (Tenecteplase) as a reperfusion therapy. Because coronary revascularization 
procedures such as percutaneous coronary intervention (PCI) or coronary artery 
bypass graft (CABG), are performed at only 1 tertiary public hospital in Kwa-Zulu 
Natal, only patients who consented for both coronary angiography and 
revascularization were referred, due to limited resources. Many patients declined 
intervention and were therefore treated medically. 
 
The occurrence of MACE was recorded during hospital admission and 6 months post-
discharge.  This included the first occurrence of any of the following; cardiac failure, 
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cardiogenic shock, complete heart block, atrial or ventricular arrhythmias, recurrence 




Routine biochemistry was performed on admission using standardized techniques.  
Troponin T measured on the Elecsys 2010 (Roche Diagnostics), was considered 
positive at a cut-off value greater than 0.03ng/ml. Fasting lipograms were performed 
after an overnight fast. Low-density lipoprotein (LDL) cholesterol levels were 
calculated utilising the formula of Friedewald.33 The cut-points used to stratify 
patients were based on the updated South African Guidelines.11,12,13 Levels were 
considered abnormal if total cholesterol was > 4.5 mmol/L, LDL cholesterol >2.5 
mmol/L, triglycerides ≥ 1.7 mmol/L, and high-density lipoprotein (HDL) cholesterol 


















A total of 1311 females were screened of whom 1160 patients fulfilled the inclusion 
and exclusion criteria and were available for analyses. Of the 1160 females with AMI, 
the majority of participants were of Asian Indian origin [92.2%], Black African 
[4.4%], White [2.6%] and Coloured [0.9%] [Table 1]. The mean (SD) age of the study 
population was 61.6 ± 10.7 years and were stratified into 2 age groups; < than 65 
years [n= 666 (57.4%)] and ≥ 65 years [n= 494 (42.6%)].  
The commonest risk factors in this study group included dyslipidaemia [97.4%], 
hypertension [77%], diabetes[75.6%] and obesity [29.3%], while 59% of patients had 
a family history of premature atherosclerosis, diabetes [51.5%] and hypertension 
[46.6%]. When adjusted for age, a statistically greater number of patients < 65 years 
of age had dyslipidaemia [n=645, p-value=0.038], obesity [n=237, p-value<0.001], a 
history of smoking [n=196, p-value<0.001], and family histories of premature 
atherosclerosis [n=423, p-value<0.001], hypertension [n=341, p-value<0.001] and 
diabetes [n=376, p-value<0.001]. In contrast, patients ≥ 65 years were significantly  
more likely to present with hypertension[n=408, p-value<0.001] and a previous 
history of myocardial infarction and angina [n=75, p-value= 0.004 and n=94, p-
value= 0.03, respectively] (Table 1). 
Major adverse cardiac events were observed in 466 [40.2%] of patients with older 
patients having a significantly higher prevalence of events [46.8%] compared to their 
younger counterparts [35.3%, ] Most patients presented with ST elevation MI [74%] 
of whom only 28% received pharmacological reperfusion with Tenecteplase 
according to standard guidelines. Patients in general received optimal medical 
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treatment which included statins, dual anti-platelet, b-blockers and RAS (renin 
angiotensio system) blockers.  
Table 1 illustrates the distribution of MACE seen in the study population, cardiac 
failure was the adverse event found most commonly [54.4%] followed by death 
[28.1%], recurrence of infarction[16.5%], cardiogenic shock [15%], recurrence of 
angina [12.5%], while atrial arrhythmias [ 10.7%], ventricular arrhythmias [8.2%] and 
cerebrovascular events [6.2%] were detected less commonly.  
Figure 2 shows the angiographic characteristics of patients that underwent coronary 
angiography at another referral hospital. Only 337 patients [29%] were subjected to 
angiographic studies because most patients either declined coronary revascularization, 
presented too late for percutaneous coronary intervention (PCI) or because of other 
significant co-morbidities. The majority of patients were found to have triple vessel 
disease [TVD 48.7%], 22.6 % each had double vessel disease [DVD] and single 
vessel disease [SVD 22.6%] and 6.2% had normal coronary epicardial vessels. Of 
those that were subjected to coronary angiography, 50% (n=169) underwent CABG. 
Of the total study population only 14.6% (n=169) underwent CABG compared to 
4.7% (n=55) that received PCI+/-Stent. A majority of those that underwent CABG 
belonged to the younger (<65year ) age group (n=121) (Table 1).  
Following multivariable analysis using logistic regression, our data showed that a few 
clinical and laboratory parameters were significantly associated with MACE such as 
hyperglycaemia [p=0.006], hyperuricaemia [p= 0.001] and hypertriglyceridaemia [p= 







Multiple studies have indicated that females are understudied and undertreated with 
regards to CAD1,5 because CAD has always been noted to be one of the leading 
causes of death and disability in males worldwide. This study shows that CAD is also 
prevalent in the female population, who also have an increased likelihood of 
developing MACE post AMI (40% of the total study population).   
 
In this study we looked at the risk factor profile of female patients presenting with 
AMI, and what we found was that in the presence of the traditional risk factors 
(diabetes mellitus, hypertension, dyslipidemia, obesity, cigarette smoking and a 
family history of coronary artery disease) for AMI, female patients were, like their 
male counterparts, predisposed to developing AMI.2 The Framingham study17 has 
shown that the traditional risk factors for CAD in males, is applicable in females as 
well, and our study confirms that in the presence of these risk factors, females are at 
similar risk of developing CAD and more importantly, that they can present at an 
earlier age than previously thought.1,17 There were a total of 3698 patients (males and 
females) admitted to the Coronary Care Unit at RKKH during the study period and 
females with a diagnosis of AMI comprised 32% (n=1160) of that population. The 
commonest risk factors for AMI in our study were HPT, DM, Obesity (BMI), and 
family histories of CAD, DM and HPT. Although these risk factors were prevalent 
across both age groups of the study population, our study emphasized the fact that age 
is not a protective factor for females developing AMI, as was previously thought in 
other studies.1 We had a greater proportion of our patients in the younger (<65years) 
age group (57% vs 43%). Furthermore the prevalence of DM, obesity (BMI), 
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dyslipidemia, smoking and family histories of DM, HPT and CAD were higher in the 
younger population which emphasizes the fact that these traditional risk factors play a 
big role in increasing the risk of the development of AMI irrespective of age or 
gender.  
 
Previous studies have shown that women tend to present with coronary artery disease 
on average 6-10 years later (around 69-70 years of age) than their male counterparts2 
and this was believed to be in part due to the cardio-protective role of oestrogen.2 In 
contrast, the majority of patients in our study presented in the younger age group and 
this concurs with previous reports which showed that the average age of presentation 
in females in developing countries tends to be lower than that of westernized 
countries (62 years versus 69-70 years in western countries).2,3,23 
 
Very few studies have been undertaken in the South African setting and the majority 
of information that we have on CAD in our female population has been obtained from 
other parts of Africa, with the Interheart study providing some valuable information.16 
One study on CVD in Africa showed that females had a higher prevalence of 
hypertension, obesity and hyperlipidemia compared to men, with Hypertension being 
the major risk factor for females.18 Other studies have shown that the major risk 
factors for females with CAD are diabetes mellitus and hypertension +/- 
dyslipidemia.19,20  These studies however did not compare females of different age 
groups. Both DM and HPT were prevalent in both age groups in our study, with total 
values for DM and HPT being 76% and 77% respectively. Furthermore, for DM, the 
percentages where similar in each age group, with 76% in the <65 year age group and 
75% in the > 65 age group (Table1). The large proportion of patients with family 
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history of vascular disease in our study re-emphasizes the significance of heritable 
disease in contributing to the risk of CAD. 
 
Furthermore, besides the traditional risk factors (mentioned above) for AMI, we 
found in our study that hyperglycemia, hypertriglyceridemia and hyperuricemia were 
independent risk factors for the development of CAD and also negatively contributed 
to the development of MACE. Hyperuricemia is the end product of purine metabolism 
and its role as an independent risk factor in cardiovascular disease is still being 
debated.34 Several patho-physiological mechanisms on how hyperuricemia 
contributes as a risk factor for CAD have been postulated including endothelial 
dysfunction, oxidative metabolism, and platelet adhesiveness and aggregation. 
 
Several studies have shown that females have poorer outcomes following acute 
myocardial infarction and have higher mortality rates compared to men.1,3 In our 
study we found a large proportion of our patients to have developed MACE (n=466, 
40%). This was greater than in any of the studies we had reviewed. The commonest 
adverse events in our study were cardiac failure (55%, n= 255) followed by death 
(28%, n=131) and this was similar to adverse events in other studies.23,25 The reasons 
for poorer outcomes are not well understood but are possibly linked to an array of 
events, including delayed presentation to hospital, refusal of medical therapies and 
invasive interventions, as well as the pathophysiological factors such as smaller 
coronary vessels in females with fewer collaterals. One possibility is that the 
prevalence of DM is so high in our study population and the cardiovascular disease 
risk is increased in the presence of diabetes mellitus. Cardiac failure, cardiogenic 
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shock and death had a slightly higher rate in the older females, whereas recurrence of 
angina seemed to occur more in the younger population. 
 
Although most studies reported on males and females found that STEMI was less 
common in females26 in our study 74% of subjects had STEMI (n=858).  In addition, 
only a small proportion of those with STEMI went on to receive thrombolysis with 
Metalyse (n=325, 38%). This is in keeping with other studies were only a small 
proportion of females received thrombolysis.24,25 
The reasons for this may be multifactorial and could include delayed presentation to 
hospital, prolonged door to needle times for various reasons, or patients declining 
therapy. These are some of the reasons that have been found particularly amongst 
females in international studies1,5.  
A small proportion of our patients were up-referred for invasive intervention in the 
form of angiogram (n=337, 29%). The reasons for this again could most likely be 
patients declining further intervention and this would be in keeping with international 
studies5.  
Of the patients that did agree to Angiogram a majority were found to have triple 
vessel disease (48.7%) indicating the severity of the disease in this population and the 
importance of early screening for the disease (Graph 2). Of the patients that 










A few potential limitations merit consideration. Firstly, this was a single center study 
of a predominantly Asian Indian population and a racial selection bias may exist 
because of this. This is important because we could not adequately compare race 
groups to determine if risk factors for AMI in females differ in different racial groups.  
Secondly, we had no available data on which of our patients belonged to the pre and 
post-menopausal age groups and as such were unable to accurately provide results 
that may have made a confounding difference in view of the believed cardio-
protective role of oestrogen in premenopausal women. Thirdly, we had no 
information on which, if any our patients were receiving Hormone replacement 
therapy at the time of presentation with their acute MI, and given the assumed 
protective effects of female hormones on the endothelium, we cannot conclude on this 
further. Finally, although a majority of our patients had STEMI (n=858) only a small 
proportion received thrombolysis with Metalyse (n=325), due to late presentation or 
because of other contraindications to lytic therapy. Similarly, only 29% of patients 
were subjected to coronary angiographic studies, which are performed at another 
tertiary center (only one such center is capable of performing these procedures in the 
public domain in the province of Kwa-Zulu Natal), and therefore results for these 








There were 2 major outcomes from our study.  Firstly, we found that younger females 
presented with AMI in the presence of traditional risk factors for CAD. Females in 
our study comprised 32% of the total population of acute MI admitted to the study 
center, and of that >50% of patients were younger than the age of 65years. This is 
younger than the average age of presentation of females with AMI in other studies2,3,5 
and raises the question  as to whether female hormones are cardio-protective in the 
presence of traditional risk factors for CAD. We also found that younger females tend 
to have multiple risk factors, of which a large proportion had diabetes mellitus and/or 
hypertension and dyslipidemia. There were also strong positive family histories for 
DM, HPT and CAD. This emphasizes the fact that heritable conditions contribute 
significantly to the risk of developing AMI, and is in keeping with other studies.   
The second biggest outcome of our study was the large proportion of patients that 
developed MACE with 466 subjects (40%) having developed some form of MACE, 
with over a half of this being cardiac failure (54,7%) and over a quarter being death 
(28%) we and believe that this is quite significant and proves that females are at an 
increased risk of developing MACE post MI.1,3,19  
According to a 2013 update on coronary artery disease in women,5 it was stated that 
coronary artery disease is the leading cause of mortality in females and requires 
further sex-specific research on the disease. As such we need to be more vigilant in 
our screening and treatment of the female population presenting with risk factors that 
predispose them to CAD.  	
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																					TABLE 1: Baseline characteristics according to age 
 
 








RACE :                                             Asian 1069(92.2%) 595 (55.7%) 474 (44.3%)   
                                                           Black 51 (4.4%) 41(80.4%) 10(19.6%)   
                                                     Coloured 10 (0.9%) 9(90%) 1(10%)   
                                                          White 30 (2.6%) 21(70%) 9(30%)   
      
RISK FACTORS:        Diabetes Mellitus  877(75.6%) 507 (76.1%) 370 (74.9%)  0.63 
                                              Hypertension 897 (77%) 489 (73.4%) 408 (82.6%)  <0.001 
                                                Dylipidemia 1130 (97.4%)  645 (98.9%) 465 (97.3%)  0.038 
                                            Obesity (BMI)  340 (29.3%)  237 (35.6%) 103 (20.9%)  <0.001 
                                                     Smoking 243 (21%) 196 (29.4%) 47 (9.5%)  <0.001 
                  Previous Myocardial infarction 139 (12%) 64 (9.6%) 75 (15.2%)  0.004 
                                         Previous Angina 189 (16.3%) 95 (14.3%) 94 (19%)  0.03 
      
FAMILY HISTORY:                             
                              Coronary artery disease 683 (59%) 423 (63.5%) 260 (52.6%)  <0.001 
                             Cerebrovascular disease 229 (19.7%) 145 (21.8%) 84 (17%)  0.044 
                                              Hypertension 540 (46.6%) 341 (51.2%)  199 (40.3%)  <0.001 
                                        Diabetes Mellitus 597 (51.5%) 376 (56.5%) 221 (44.7%)   <0.001 
      
MEDICATION AT DISCHARGE:           
                                                       Nitrates 1145(98.7%) 659 (98.9%) 486 (98.3%)  0.397 
                                                        Disprin 1154(99.5%) 664 (99.7%) 490 (99.2%)  0.232 
                                                         Statins 1097(94.6%) 640 (96.1%) 457 (92.5%)  0.008 
                                             ACE-I/ARB'S 964 (83.1%) 556 (83.5%) 408 (82.6%)  0.688 
                                             Beta-Blockers 753 (64.9%) 455 (68.3%) 298 (60.3%)  0.005 
                          Calcium channel blockers 110 (9.5%) 68 (10.2%) 42 (8.5%)  0.326 
      
MACE  466 (40.2%) 235 (35.3%) 231 (46.8%)  <0.001 
STEMI 858 (74%) 505 (75.8%) 353 (71.5%)  0.094 
NSTEMI 300 (25.9%) 160 (24%) 140 (28.3%)  0.097 
Metalyse 325 (28%) 207 (31.1%) 118 (23.9%)  0.007 
Coronary Angiogram 337 (29.1%)     
PCI +/- STENT  55 (16.3%) 45 (13.4%) 10 (3%)  <0.001 
CABG 169 (50.1%) 121 (35.9%) 48 (14.2%)  <0.001 
CONTINUOUS VARIABLES  TOTAL <65years >65years Mean +SD P-Value 




(42.6%)   
Systolic BP(mmHg) 1160 135.4 (29.2) 137.6 (29.8) 136.4+  29,5 0.22 
Diastolic BP(mmHg) 1160 81.1 (17.9) 77.0 (16.6) 79.4 + 17.6 0.0001 
Abdominal Girth(cm) 905 (78.0%) 100.6 (13.2) 98.5 (12.7) 99.8 + 13.0 0.0182 
      
BIOCHEMICAL DATA       
Total Cholesterol (mmol/L) 846 (72.9%) 5.6 (1.4) 5.3 (1.3) 4.8 + 0,2 0.100 
LDL cholesterol (mmol/L) 1083 (93.4%) 3.5 (1.2) 3.4 (1.1) 2,6 + 0,1 0.3314 
HDL cholesterol (mmol/L) 1113 (95.9%)  1.1 (0.5) 1.1 (0.4)  1.1 + 0.06 0.1655 
Trigylcerides (mmol/L) 1126 (97.1%) 2.3 (1.7) 1.7 (0.9) 2.4 + 0.1 <0.001 
Haemoglobin (g/dL) 1155 (99.6%)  12.4 (1.9) 11.8 (1.9) 10.9 + 0.6 <0.001 
Creatinine (mmol/L) 1156 (99.7%)  93.9 (58.5) 111.9 (76.0) 101.6 + 67.2 <0.001 
Uric Acid (mmol/L) 1083 (93.4%)  0.4 (0.1) 0.4 (0.1)  0.4+ 0.02 0.0001 
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• 1160 patients  is our study population, however it made up  88.5% of the total number of 
females presenting to the study centre with chest pain. The 1160 patients are those with a 
diagnosis of AMI. 
• Significant p-values have been marked in bold.  
BMI: Body mass index 
ACE-I/ARB’S: Angiotensin converting enzyme inhibitor/Angiotensin receptor blockers 
MACE: Major adverse cardiac events 
STEMI: ST elevation myocardial infarction 
NSTEMI: Non ST elevation myocardial infarction 
PCI: Percutaneous coronary angriography 





TABLE 2: Logistic Regression Analysis: Predictors of Mace 	
CHARACTERISTICS ODDS RATIO (95% CI)  STD ERROR P-VALUE  
Age >=65 1.25 (0.91-1.70) 0.20 0.162 
Dyslipidemia 0.87 (0.27-2.82) 0.52 0.817 
Central obesity 1.53 (0.65-3.61) 0.67 0.333 
Diabetes 1.43 (0.95-2.17) 0.30 0.089 
Hypertension 0.93 (0.64-1.35) 0.18 0.698 
Smoking 0.77 (0.52-1.14) 0.15 0.190 
Family Hx CAD 0.77 (0.57-1.03) 0.12 0.082 
STEMI 1.09 (0.78-1.53) 0.19 0.597 
Elevated Urea (mmol/l) 1.05 (0.99-1.11) 0.31 0.112 
Elevated Creatinine (mmol/l) 1.00 (0.99-1.00) 0.00 0.201 
Hyperglycaemia (mmol/l) 1.04 (1.01-1.07) 0.01 0.006 
Hypertriglyceridemia (mmol/l) 0.86 (0.76-0.97) 0.05 0.014 





















































								GRAPH 2:  Angiographic characteristics of the study population    
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5.4     If “yes” to (5.3), please provide SANCTR registration number: N/A 
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5.6   Please provide the names of all members of the Data Safety and Monitoring Board (DSMB) (CLINICAL TRIALS 
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7.      BIOLOGICAL SAMPLES 
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8.2    Has the nursing team who will be involved in the study been informed of 
the study and the nursing involvement which will be required? Nursing 
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8.3   In the case of participants drawn from patient populations, indicate, in respect of each sub-group, how 
management differs from that usually offered to patients with similar conditions.  N/A 
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following stages:  N/A 
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8.5.1.1 Clinical care: There is a gender bias in terms of publication and females have been a poorly studied 
group with regards to coronary artery disease, so we hope that the data derived from this study will 
help narrow that gap and improve outcomes for coronary care in female patients. 
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8.5.1.2 Public health: We will be able to determine if female patients with coronary artery disease behave 
differently to their male counterparts 
8.5.1.3 Financial: The results of the study will be of benefit to all centres admitting female patients with acute 
myocardial infarction and by improving the management of this patient population there will be 
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8.5.2 Specify the Indirect benefits arising from this study: This study will assist in drawing up guidelines for 
cardiovascular disease in the female population and will impact on future management and outcomes 
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8.6    Describe the intended strategy for dissemination of study results 
8.6.1 To the scientific community: By publication in a scientific journal 
8.6.2 To research participants: They can be informed of the scientific journal that the article has been 
published in. 
8.6.3 To the general public (if applicable):  If the results of this study are profound then It would be possible to 
get a newspaper publication.  
8.6.4 Other: Specify: NIL 
 
9. RESEARCH DATA/SAMPLES 
9.1     Please explain where the data/samples will be stored and how long they will be stored for? Data is currently 
stored on a computerized database where it will remain for the timeframe of the study and thereafter.  
9.2     Will data/samples be destroyed after analyses? Data will be stored for at 
least 15years in the Database.  












See SAMPLE INFORMATION SHEET AND CONSENT FORM ON UKZN BREC WEBSITE at 
http://research.ukzn.ac.za/Libraries/Notices2011/BREC_Informed_consent_form_sflb.sflb.ashx   
  
Other consent forms are acceptable provided that they contain at least the essential elements outlined in the current 
UKZN BREC Terms of Reference (ToR) and Standard Operating Procedures (SoP) available 
a15http://research.ukzn.ac.za/Research-Ethics/Biomedical-Research-Ethics.aspx   
  
If necessary, information sheets and consent forms, after ethics approval of the English version, must be translated 
into appropriate local languages and submitted to BREC for further approval prior to implementation, with a copy of the 
translator’s certificate, and back translations if applicable.  
  
The correct and complete contact details for the UKZN Biomedical Research Ethics Committee should be in the 
information sheets and consent forms as follows:  
  
BIOMEDICAL RESEARCH ETHICS ADMINISTRATION  
Research Office, Westville Campus  
Govan Mbeki Building  
University of KwaZulu-Natal 
Private Bag X 54001, Durban, 4000  
KwaZulu-Natal, SOUTH AFRICA  
Tel: 27 31 2602486 - Fax: 27 31 2604609  
Email: BREC@ukzn.ac.za    
  
11.    QUESTIONNAIRES: GIVEN TO PARTICIPANTS 
Not applicable as the study is a Retrospective chart review in which data will be extracted from an existing 
database. Patient anonymity will be maintained. 
Provide 25 copies of all questionnaires, interview guides, data collection sheets etc.  
	 XIV	
List all such attachments here:   
DATA COLLECTION TOOL 
 
12.    DECLARATION OF PRINCIPAL INVESTIGATOR 
Conflict of Interest:  
 
I declare that all potential conflicts of interest regarding my application for ethics approval to conduct this study have 
been declared in accordance with UKZN and BREC Terms of Reference and Standard Operating Procedures.   
  













I understand and accept that I will be required to submit a yearly recertification application, failing which authorisation 
to continue the study lapses. Progress reports may be required more frequently depending on level of risk and other 
factors – this will be detailed in the BREC approval letter. Where applicable, all reports from the Data Safety Monitoring 
Boards (or similar committees) will be provided to the Biomedical Research Ethics Committee within 7 days.  
  
I undertake to request permission for any changes/amendments to the study from BREC in advance of implementing 
any such changes, unless they are emergencies required to prevent harm or save life. In such cases BREC must be 
notified urgently.  
  
I agree to provide monitoring data if and when required.  
  
I expect the project to be completed by Date…………………………………   
  
I agree to abide by the guidance contained in the SA Department of Health (2015) Ethics in Health Research: 
Principles, structures and processes and the (2006) South African Good Clinical Practice Guidelines and the current 
UKZN Biomedical Research Ethics Committee Terms of Reference and Standard Operating Procedures. These are 
available at http://research.ukzn.ac.za/Research-Ethics/Biomedical-Research-Ethics.aspx 
  
 
I understand and accept that all information pertaining to this application is a true reflection of the project proposed and 
I take full responsibility should there be any transgression.  
  
SIGNATURE OF PRINCIPAL INVESTIGATOR…………………………………… 
 




13.    DECLARATION AND APPROVAL FROM SUPERVISOR AND CO-SUPERVISOR (if applicable) 




SIGNATURE OF SUPERVISOR ………...……………………………… 
 






SIGNATURE OF CO-SUPERVISOR ………...……………………………… 
 






If applicable, attach a signed copy of the Supervision Agreement between the student, supervisor and any co-
supervisor. 
 
14.    DECLARATION AND APPROVAL OF LINE MANAGER/HOD/ACADEMIC LEADER 






SIGNATURE OF ACADEMIC LEADER/HOD OR LINE MANAGER …………………………………… 
 




NB: If applicant is ACADEMIC LEADER/DEAN/HOS, the ACADEMIC LEADER’S/DEAN’S/HOS’s Line Manager (DVC) 
must sign. 
      
 
SIGNATURE OF ACADEMIC LEADER’s/ HOS’s/DEAN’s Line Manager…………………………………… 
 












																															SUGGESTED CURRICULUM VITAE FORMAT	
  
(3 COPIES AND MAXIMUM 4 PAGES)  
  
CURRICULUM VITAE (of Principal Investigator and all Co-Investigators) 
(CVs to be completed and signed for each member of the research team) 
  
Full name:  
Date of birth:  
Male/Female:  
Telephone (Home):  
Telephone (Business):  
Cell:  
Fax No:  
E-mail Address:  
Current HPCSA No:  (or equivalent statutory health council registration No. as appropriate)  
Present position:  
Institution:  
Department/Section:  
Nationality/Permanent residency:  
Previous positions held (last 10 years):  
Qualifications:  
University where obtained/year:  
Area of study:  
Number of Postgraduate theses supervised (Masters and Doctoral):  
Publication list over the past 3 years:  
Details of all other research studies presently being conducted:  
Certificate of recent (past 3 years) research ethics and/or GCP training (GCP required for 














CHECKLIST FOR BIOMEDICAL RESEARCH ETHICS APPLICATIONS  
NB:  DO NOT BIND SUBMISSIONS (STAPLE ONLY)  
  
Applications to be addressed to: The Administrator, Biomedical Research Ethics 
Committee, Govan Mbeki Building, University Road, Westville Campus, Tel:  031-260 
4769 / 2486  Email: BREC@ukzn.ac.za  
 
Note to Students:  
PLEASE NOTE THAT ONLY ONE  COPY OF APPLICATION AND SUPPORTING 
DOCUMENTS NEED BE SUBMITTED IF STUDY IS FOR DEGREE PURPOSES.  ALL 
APPLICATIONS FOR DEGREE PURPOSES MUST BE SUBMITTED VIA THE COLLEGE 
POST-GRADUATE OFFICE WITH AN APPROVAL LETTER ATTACHED. 
  
INCOMPLETE SUBMISSIONS MAY RESULT IN DELAYED REVIEW OF THE APPLICATION  
 
For all non-degree, non-expedited (full) review 
applications: 
  
 • 25 TYPEWRITTEN COPIES OF APPLICATION (Back-to-back (double-sided) copies 
preferred)   
 • 5 COPIES OF THE PROTOCOL   
 • 5 COPIES OF CURRENT CV/s (abbreviated 2 PAGES)   
 • 5 COPIES OF EVIDENCE OF CURRENT GCP / RESEARCH ETHICS TRAINING   
 • 25 COPIES OF ALL QUESTIONNAIRES TO BE USED IN THE STUDY   
 • 25 COPIES OF THE INFORMED CONSENT FORMS (See BREC templates) 
 • 25 COPIES OF THE PATIENT INFORMATION LEAFLET (See BREC templates) 
 • HAVE YOU FAMILIARISED YOURSELF WITH THE BREC TERMS OF REFERENCE?  
(See  http://research.ukzn.ac.za/Research-Ethics/Biomedical-Research-Ethics.aspx 
) 
 • DETAILS OF ALL FUNDING SUPPORT?   
 • ALL PERSONAL INFORMATION?   
 • ANSWERED ALL QUESTIONS?   
 • GIVEN DETAILS OF ALL RESEARCH PRESENTLY BEING UNDERTAKEN?  
 • DELETED UNNECESSARY BLANK SPACES IN THE DOCUMENT?  
 • IS DECLARATION PAGE SIGNED BY PI AND HOS/DEAN OR SUPERVISOR?  
  
In addition:  FOR CLINICAL TRIALS – SUBMIT:  
 • 5 COPIES OF THE INVESTIGATOR’S MANUAL 
 • 5 COPIES OF MCC APPROVAL  










FINAL CHECKLIST FOR FULL (Non-expedited) APPLICATIONS: 
 
 
1  Proof of PI and Co–PI current HPCSA registration  YES   NO  N/A  
2  Permission from hospital manager/clinics submitted  YES   NO  N/A  
3  For degree purposes, please attach copy of postgraduate approval letter  YES   NO  N/A  
4  Roles of PI & co-investigators given  YES   NO  N/A  
5  CV of PI submitted  YES   NO  N/A  
6  CV's of co-investigators submitted  YES   NO  N/A  
7  GCP/ethics training certificate of PI  YES   NO  N/A  
8  GCP/ethics training certificates of co-investigators  YES   NO  N/A  
9  Have other REC approval letters been submitted?  YES   NO  N/A  
10  Is applicant affiliated to BREC – e.g. BREC member? If yes, please 
specify  
YES   NO  N/A  
11  Clinical protocol submitted  YES   NO  N/A  
12  BREC details on Information Sheet updated/checked  YES   NO  N/A  
13  Statistics addressed  YES   NO  N/A  
14  Information to participants submitted  YES   NO  N/A  
15  Informed consent documents submitted  YES   NO  N/A  
16  Signature of PI  YES   NO  N/A  
17 Signed supervision agreement (if applicable) YES   NO  N/A  
18 Signature of  ACADEMIC LEADER/HOS/DEAN or Line Manager YES   NO  N/A  
19  Signatures of co-investigators  YES   NO  N/A  
20  Questionnaires submitted  YES   NO  N/A  
21  Translation of documents certified YES   NO  N/A  
22 Materials Transfer Agreement (MTA) YES NO N/A 
23 Will genetic studies be performed?  If yes, provide consent form YES NO N/A 
24 Export certificate for tissue storage/transportation  YES   NO  N/A  
25 Permission from Department of Health/Province YES   NO  N/A  
26 One copy of grant funding proposal and Award notice if funded by any 
US DHHS source, e.g., NIH, CDC, DAIDS 
YES NO N/A 
27 
 
















Appendix 4: The Guidelines for Authorship for the Journal selected 

















Appendix 6: Raw data (sample)  
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